2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by D’Amico, G. Search for Related Content PubMed PubMed Citation Articles by D’Amico, G.

Statins and Renal Diseases: From Primary Prevention to Renal Replacement Therapy

Department of Nephrology and Immunology, San Carlo Hospital, and Fondazione "D’Amico" per la Ricerca sulle Malattie Renali, Milan, Italy

Address correspondence to: Dr. Giuseppe D’Amico, Fondazione "D’Amico," per la Ricerca sulle Malattie Renali, c/o Ospedale San Carlo Borromeo, Via Pio II 3, 20153 Milan, Italy. Phone: +39-02-48705804; Fax: +39-02-40222222; E-mail: giuseppe.damico{at}scb.sined.net

In glomerular diseases with nephrotic syndrome or protracted severe proteinuria, alterations of the lipid metabolism occur and are characterized mainly by increase of LDL cholesterol and frequently also of triglycerides and by qualitative abnormalities of HDL cholesterol and LDL cholesterol. In all renal diseases, when renal insufficiency develops, hyperlipidemia also occurs, with a near-elective increase in VLDL and intermediate-density lipoprotein cholesterol and a decrease of mature HDL cholesterol. There is clear evidence that these abnormalities may induce cardiovascular complications and, probably, also an accelerated progression of the renal damage. The inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase, the so-called statins, are effective in controlling hypercholesterolemia, even in the more advanced stages of renal failure and in patients who are on maintenance dialysis. This antilipidemic effect of statins combines with other effects—antioxidant, anti-inflammatory, immunomodulatory, and antithrombotic (called "pleiotropic" effects)—as a result of the inhibition of the mevalonate pathway induced by these agents. Also because of these non–lipid-dependent effects, statins could have an antiatherosclerotic and renoprotective effect, which has been demonstrated clearly in vivo on renal cells and in experimental models of nephropathy but is still less evident in human renal diseases. Ongoing large trials will establish more clearly whether such effects are present in renal patients.

This article has been cited by other articles:

				J. A. Joles Statins and small GTPases: Koch's postulates and chronic kidney disease Nephrol. Dial. Transplant., February 1, 2008; 23(2): 433 - 438. [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673